Rystiggo MG denied as not medically necessary by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rystiggo (rozanolixizumab-noli) for Medical Necessity — and Why You Can Appeal

Cigna's medical-necessity denials for Rystiggo in generalized myasthenia gravis (gMG) typically occur when the insurer's reviewer concludes the clinical record does not establish that the patient meets the plan's criteria for a biologic agent — for example, that the patient's disease is not sufficiently severe, that required prior therapies have not been adequately tried, or that the prescribing information's intended patient population has not been documented. These denials often reflect an incomplete record submission rather than a genuinely inappropriate prescription, and they are among the most commonly overturned denial categories when the treating neurologist provides a detailed, criteria-aligned letter.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered plans must provide independent external review after internal appeals. ERISA Section 503 requires that employer-sponsored plans provide a full-and-fair review with a written decision specifying every reason for denial. If your gMG is in active exacerbation, crisis, or is otherwise urgent, expedited appeal is available and must be decided on a significantly compressed timeline. The external review window generally extends roughly four months from the date internal remedies are exhausted.

## The Appeal Process and Timeline

1. Obtain the denial in writing — the letter must state every specific reason and cite each plan provision relied upon. 2. File a first-level internal appeal within the timeframe stated on the denial (often 180 days). This is your opportunity to submit all missing or additional documentation. 3. If denied, proceed to second-level internal appeal if available, then external review. 4. Request a peer-to-peer clinical discussion between your neurologist and Cigna's medical director early in the process — many medical-necessity denials resolve at this stage once the full clinical picture is presented.

## Documentation to Gather

• Diagnosis confirmation: records establishing gMG diagnosis, antibody status (AChR, MuSK, or seronegative), and disease classification by severity.
• Prior treatment history with dates and outcomes: a chronological list of all gMG treatments tried — acetylcholinesterase inhibitors, steroids, steroid-sparing immunosuppressants, IVIg, plasma exchange — with dates of initiation, duration, doses (from the chart), and documented clinical response or reason for discontinuation.
• Clinical severity documentation: objective measures of disease activity in the chart — functional scale scores, respiratory function assessments, frequency and severity of myasthenic events or crises, impact on activities of daily living.
• Neurologist medical-necessity letter: a detailed letter from the treating neurologist mapping the patient's clinical situation to each of Cigna's stated coverage criteria for Rystiggo, explaining the mechanism of action, why prior therapies were insufficient, and what clinical goals Rystiggo is intended to achieve.
• Applicable guideline reference: cite the applicable neurology or myasthenia gravis society guideline that supports biologic therapy in refractory gMG.

## Criteria-Mapping Structure

Download Cigna's published coverage policy for Rystiggo or FcRn inhibitors for gMG. Build a table with every listed coverage criterion in the left column and the specific chart fact or supporting document in the right column. If any criterion is met only partially or indirectly, address it explicitly rather than leaving it blank — reviewers will note omissions. Include the FDA-approved prescribing label criteria in a parallel column to show alignment between the label indication and Cigna's policy.